Is the conclusion justifiable?
The obvious weakness of the study of Chocron et al. 1 is that it is a re-analysis of the primary end-point of the IMAGINE trial according to whether the patients had undergone PCI prior to CABG, a question which the IMAGINE trial was not designed to answer. Rather, IMAGINE was a randomized trial of the angiotensinconverting enzyme (ACE) inhibitor quinapril in 2553 subjects with preserved left ventricular function after CABG, which concluded that there was no difference in time to occurrence of the primary end-point (a composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, coronary revascularization, unstable angina requiring hospitalization, documented angina not requiring hospitalization, stroke, or congestive heart failure requiring hospitalization) in the active or placebo group. 3 Re-emphasizing that IMAGINE was not actually designed to investigate the effects of prior PCI, the two groups were otherwise relatively similar. Although the 455 patients in the prior PCI group had a higher incidence of previous myocardial infarction, the overall ejection fraction was similar to that in the 2098 patients in the non-PCI group who also had a higher incidence of left main stem stenosis and multivessel disease. In the current analysis, there was a significant increase in the primary end-point in the prior PCI group [hazards ratio (HR) ¼ clear from the literature whether the 'new culprit' lesion is related to the previous PCI or de novo remote disease. Other possibilities might be that prior stents encourage more distal bypass grafting with less favourable graft run off, or may compromise collateral blood flow. 8 While it is well recognized that drug-eluting stents (DES) cause dysfunction of the endothelium both overlying the stent and further downstream, 9 is it possible that bare metal stents (BMS) also compromise endothelial function overlying the stent which is exaggerated by changes in the inflammatory and coagulation status precipitated by cardiac operations?
Will the findings be different with drug-eluting stents?
A potential criticism of the studies by Chocron, Hassan, and Thielmann is that PCI may have been suboptimal as there was a relatively low use of DES in comparison with BMS. However, as several meta-analyses have consistently demonstrated that while DES reduce the risk of restenosis in low-risk coronary lesions they do not reduce the risk of mortality or subsequent myocardial infarction, 10 it is counter-intuitive to believe that they will improve results post-CABG.
There is a further concern with DES: the FDA have warned that their use is 'associated with increased risks of both early and late stent thrombosis, as well as death and myocardial infarction'.
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DES impair endothelialization, leaving a potentially prothrombotic substrate within the vessel, 12 and leave a further conundrum for the surgeon in terms of control of antiplatelet medication and whether to perform bypass grafts to a coronary vessel with a DES without critical restenosis in patients who have multivessel disease. These clinical concerns are compounded by cost implications; not only are DES significantly more expensive than BMS, but new recommendations that patients remain on clopidogrel for at least a year, and possibly indefinitely, add significantly to overall costs.
What are the clinical implications for patients and the economic implications for health services?
In economic terms there is already strong evidence that stenting in multivessel coronary artery disease is not a cost-effective treatment, 13 and the studies of Chocron and others will add to these concerns. However, the major implication of the finding that prior PCI increases the risk of subsequent CABG is to add ammunition against the spurious belief that CABG can always be safely deferred in favour of an initial strategy of PCI in multivessel disease, where several large registries already show a consistent survival advantage for CABG over PCI in propensity-matched patients. 2, 10 These dual observations should be carefully considered in patients with multivessel disease who are likely eventually to require CABG, and underline the importance of the proposed interventions being discussed by a multidisciplinary team including a surgeon rather than by the individual cardiologist.
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